Ambu A/S Reports Strong Q3 Growth and Strategic Advances

Ambu A/S Class B ( (AMBFF) ) has released its Q3 earnings. Here is a breakdown of the information Ambu A/S Class B presented to its investors.

Ambu A/S Class B, a leader in the medtech industry, specializes in developing and providing innovative endoscopy solutions and other medical devices. In its latest earnings report for Q3 2024/25, Ambu A/S reported a robust organic revenue growth of 12.0%, driven by strong performances in its Endoscopy Solutions and Anesthesia & Patient Monitoring segments. The company also highlighted strategic advancements, including the expansion of its pulmonology and urology offerings, and the launch of a unique endoscope recycling program.

The financial results for the quarter showed an increase in revenue to DKK 1,507 million, with Endoscopy Solutions leading the growth at 15.9%. The Pulmonology business group saw an 11.2% growth, while the Urology, ENT, & GI segment posted a remarkable 20.8% increase. Despite facing FX headwinds and tariff costs, the company maintained a solid EBIT margin before special items of 11.3%. Free cash flow before acquisitions was DKK 128 million, reflecting the company’s strategic investments and operational efficiencies.

Ambu’s commitment to sustainability was underscored by the launch of the Ambu Recircle Program, aimed at recycling used endoscopes. The company also continued to focus on reducing carbon emissions and enhancing energy efficiency, aligning with its long-term sustainability goals. These initiatives, coupled with strategic product expansions, position Ambu well for future growth.

Looking ahead, Ambu has raised its lower-end organic revenue growth guidance to 12-14% for the full year, supported by continued procedure growth and a shift towards single-use solutions. The company remains focused on long-term growth investments, despite external challenges such as FX fluctuations and tariff costs.